Amneal Pharmaceuticals, Inc. $AMRX Shares Bought by Deutsche Bank AG

Deutsche Bank AG boosted its stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 128.3% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 305,621 shares of the company’s stock after buying an additional 171,735 shares during the period. Deutsche Bank AG owned 0.10% of Amneal Pharmaceuticals worth $2,561,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Janney Montgomery Scott LLC raised its position in Amneal Pharmaceuticals by 26.9% in the first quarter. Janney Montgomery Scott LLC now owns 19,350 shares of the company’s stock valued at $162,000 after purchasing an additional 4,100 shares during the period. Allspring Global Investments Holdings LLC boosted its position in shares of Amneal Pharmaceuticals by 53.4% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 60,567 shares of the company’s stock worth $508,000 after acquiring an additional 21,079 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Amneal Pharmaceuticals by 45.7% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 318,420 shares of the company’s stock valued at $2,522,000 after purchasing an additional 99,866 shares during the period. California State Teachers Retirement System boosted its position in shares of Amneal Pharmaceuticals by 10.3% in the 4th quarter. California State Teachers Retirement System now owns 131,713 shares of the company’s stock valued at $1,043,000 after purchasing an additional 12,282 shares during the period. Finally, BNP Paribas Financial Markets raised its stake in Amneal Pharmaceuticals by 209.2% during the 4th quarter. BNP Paribas Financial Markets now owns 168,194 shares of the company’s stock valued at $1,332,000 after acquiring an additional 113,796 shares during the last quarter. Hedge funds and other institutional investors own 31.82% of the company’s stock.

Analysts Set New Price Targets

AMRX has been the subject of a number of analyst reports. Wall Street Zen downgraded Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, May 13th. The Goldman Sachs Group initiated coverage on Amneal Pharmaceuticals in a report on Friday, June 6th. They set a “buy” rating and a $12.00 price objective on the stock. Five equities research analysts have rated the stock with a Buy rating, According to MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $11.60.

Amneal Pharmaceuticals Price Performance

Shares of AMRX stock opened at $9.33 on Wednesday. Amneal Pharmaceuticals, Inc. has a 12-month low of $6.68 and a 12-month high of $9.59. The firm has a market capitalization of $2.93 billion, a price-to-earnings ratio of 933.93 and a beta of 1.11. The business has a 50 day simple moving average of $8.28 and a 200 day simple moving average of $7.98.

Amneal Pharmaceuticals (NASDAQ:AMRX) last released its earnings results on Tuesday, August 5th. The company reported $0.23 earnings per share for the quarter, topping analysts’ consensus estimates of $0.17 by $0.06. Amneal Pharmaceuticals had a negative return on equity of 189.49% and a net margin of 0.12%. Amneal Pharmaceuticals has set its FY 2025 guidance at 0.700-0.750 EPS. On average, equities analysts anticipate that Amneal Pharmaceuticals, Inc. will post 0.53 EPS for the current fiscal year.

Insider Transactions at Amneal Pharmaceuticals

In other news, EVP Nikita Shah sold 71,694 shares of the company’s stock in a transaction on Thursday, August 14th. The shares were sold at an average price of $9.29, for a total value of $666,037.26. Following the transaction, the executive vice president directly owned 267,235 shares of the company’s stock, valued at approximately $2,482,613.15. This represents a 21.15% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Andrew S. Boyer sold 33,436 shares of the stock in a transaction on Tuesday, August 12th. The stock was sold at an average price of $9.05, for a total transaction of $302,595.80. Following the transaction, the executive vice president directly owned 256,670 shares in the company, valued at $2,322,863.50. The trade was a 11.53% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 177,130 shares of company stock valued at $1,619,733. 17.45% of the stock is owned by insiders.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.